secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nexalin Technology, Inc. (NXL)
CIK:        0001527352
Form:       8-K
Filed at:   2026-10-01T21:00:14+00:00
Accession:  0001829126-26-010685
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Nexalin signs 10-year exclusive distribution deal for Nexalin Sync across seven South American countries
--------------------------------------------------------------------------------

- 10-year exclusive distribution rights for Nexalin Sync across Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela (300M+ people), auto-renewing for successive 10-year terms.
- Binding initial purchase order at signing; 5 Nexalin Sync devices delivered for a Brazil clinical pilot targeted within 90 days, with 5 more ordered within 12 months.
- Initial 100-device commercialization program with tiered per-device pricing; exclusivity requires minimum revenue to Nexalin within 30 months of pilot launch, then annually.
- At 30 devices purchased, distributor INOVANEXA MEDICAL TECHNOLOGIES S.A. must build a Brazil plant at its own cost; Nexalin gets fixed per-device fees plus royalties on disposable electrodes.
- Nexalin keeps all IP and exclusively supplies encrypted circuit boards; ANVISA approval covers anxiety, depression and insomnia; USP trial reported 77.8% anxiety response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527352/000182912626010685/0001829126-26-010685-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527352/000182912626010685/nexalintec_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-010685

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer